Breaking
● GLP-1 trial shows 34% reduction in cardiovascular events over 5 years ● Senolytics drug enters Phase III — first human trial results expected Q1 2027 ● FDA fast-tracks CRISPR base-editing therapy for sickle cell disease ● Longevity biotech index up 12% YTD as institutional capital accelerates ● AI diagnostic platform achieves 97.2% accuracy in early-stage pancreatic cancer detection ● Harvard study links CGM use to 23% lower all-cause mortality in non-diabetics
Impact Health Magazine
Impact Health digital magazine
Digital Magazine

Impact Health Magazine

The definitive publication at the intersection of health science, longevity, and the luxury lifestyle. Available in print and digital editions.

Current Issue
Impact Health Volume 4 Issue 9
September 2026
Volume 4 · Issue 9

The Longevity Economy: How a $1 Trillion Industry Is Rewriting the Rules of Aging

Read NowSubscribe
Archive

Previous Issues

The AI Diagnostics Revolution
August 2026

The AI Diagnostics Revolution

Biohacking the Billionaire Body
July 2026

Biohacking the Billionaire Body

The Swiss Longevity Circuit
June 2026

The Swiss Longevity Circuit

CRISPR: The $100 Billion Bet
May 2026

CRISPR: The $100 Billion Bet

The Family Office Health Revolution
April 2026

The Family Office Health Revolution

Senolytics: The Drug That Could End Aging
March 2026

Senolytics: The Drug That Could End Aging

Subscribe

Choose Your Edition

Digital
$9.99/mo
Full digital archive
All 9 sections
Weekly newsletter
Mobile & tablet optimized
Most Popular
Print + Digital
$24.99/mo
Monthly print edition
Full digital archive
Priority event access
Exclusive subscriber briefings
Founding Member
$199/yr
Everything in Print + Digital
Annual Summit invitation
Private investor briefings
Direct editor access